

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/24305603>

Glutathione Depletion by Buthionine Sulfoximine Induces Oxidative Damage to DNA in Organs of Rabbits in Vivo

ARTICLE in BIOCHEMISTRY · MAY 2009

Impact Factor: 3.02 · DOI: 10.1021/bi900030z · Source: PubMed

CITATIONS

17

READS

31

7 AUTHORS, INCLUDING:



Gonen Ozsarlak Sozer

Ege University

13 PUBLICATIONS 141 CITATIONS

SEE PROFILE



Güldal Kirkali

53 PUBLICATIONS 903 CITATIONS

SEE PROFILE



Pawel Jaruga

National Institute of Standards and Technol...

101 PUBLICATIONS 5,141 CITATIONS

SEE PROFILE



Zeliha Kerry

Ege University

30 PUBLICATIONS 174 CITATIONS

SEE PROFILE

Glutathione Depletion by Buthionine Sulfoximine Induces Oxidative Damage to DNA in Organs of Rabbits in Vivo[†]

Goksel Gokce,[‡] Gonen Ozsarlak-Sozer,[‡] Gulgun Oktay,[§] Güldal Kirkali,[§] Pawel Jaruga,^{||,⊥} Miral Dizdaroglu,^{||} and Zeliha Kerry^{‡,*}

[‡]Department of Pharmacology, Faculty of Pharmacy, Ege University, Bornova, Izmir, Turkey, [§]Department of Biochemistry, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey, ^{||}Chemical Science and Technology Laboratory, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, and [⊥]Department of Clinical Biochemistry, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

Received January 8, 2009; Revised Manuscript Received April 14, 2009

ABSTRACT: Glutathione (GSH) exists in mammalian tissues in vivo at high concentrations and plays an important protective role against oxidatively induced damage to biological molecules, including DNA. We investigated oxidatively induced damage to DNA by GSH depletion in different organs of rabbits in vivo. Rabbits were treated subcutaneously with buthionine sulfoximine (BSO), an effective GSH-depleting compound. GSH levels were measured in heart, brain, liver, and kidney of animals. BSO treatment significantly reduced GSH levels in heart, brain, and liver, but not in kidney. DNA was isolated from these tissues to test whether GSH depletion causes oxidatively induced DNA damage in vivo. Gas chromatography–mass spectrometry and liquid chromatography–mass spectrometry with isotope dilution methods were applied to measure typical products of oxidatively induced damage in isolated DNA samples. Several such products were identified and quantified in all organs. BSO treatment caused significant formation of 8-hydroxyguanine, 2,6-diamino-4-hydroxy-5-formamidopyrimidine, 8-hydroxyadenine, and (5′S)-8,5′-cyclo-2′-deoxyadenosine in DNA of organs of rabbits. Animals were fed with the semiessential amino acid 2-aminoethanesulfonic acid (taurine) during BSO treatment. Taurine significantly inhibited GSH depletion and also formation of DNA products. Depletion of GSH correlated well with formation of DNA products, indicating the role of GSH in preventing oxidatively induced DNA damage. Our findings might contribute to the understanding of pathologies associated with DNA damage, oxidative stress, and/or defective antioxidant responses and improve our understanding of the effect of BSO in increasing the efficacy of anticancer therapeutics.

Glutathione (L-γ-glutamyl-L-cysteinylglycine) (GSH)¹ is a pervasive tripeptide of glycine, glutamic acid, and cysteine and is known to play a crucial role in protecting tissues against the deleterious effects of oxidative damage to biological molecules. As a nucleophile, GSH also reacts with electrophilic and reactive intermediates derived from exogenous compounds such as drugs

and xenobiotics (1, 2). GSH is synthesized in the cytosol in two steps. In the first step, the enzyme γ-glutamyl cystein synthetase (γ-GCS) catalyzes the formation of L-γ-glutamyl-L-cysteine. In the second step, the glycine residue of the GSH tripeptide is added by glutathione synthetase. Cellular GSH exists at high concentrations in cells, predominantly in a reduced form, but small amounts of the oxidized disulfide form GSSG can also be detected. The GSH:GSSG ratio is generally > 100:1 and considered an indicator of cellular redox status (3, 4). Within the context of the biological importance of the role of GSH, diseases associated with GSH deficiency have been an area of considerable interest (4). Inborn metabolic deficiencies have been described for several GSH-related enzymes such as γ-GCS, GSH synthetase, and glutathione reductase. Furthermore, low GSH levels have been shown to be associated with the pathology of a number of diseases such as type II diabetes, acquired immune deficiency syndrome (AIDS), hepatitis C, ulcerative colitis, idiopathic pulmonary fibrosis, adult respiratory distress syndrome (ARDS), and cataracts (5–9). GSH is also an antioxidant and plays an important role in protecting organisms against

[†]This research was supported in part by Grant SBAG-K-70 (Z.K.) from The Scientific and Technological Research Council of Turkey (TUBITAK).

*To whom correspondence should be addressed: Department of Pharmacology, Faculty of Pharmacy, Ege University, Bornova, Izmir, Turkey. Phone: +90-232-388-5266. Fax: +90-232-388-4687. E-mail: zeliha.kerry@ege.edu.tr.

¹Abbreviations: GSH, glutathione; γ-GCS, γ-glutamyl cystein synthetase; Tau, taurine (2-aminoethanesulfonic acid); BSO, buthionine sulfoximine; 8-OH-Gua, 8-hydroxyguanine; 8-OH-Ade, 8-hydroxyadenine; 8-OH-dG, 8-hydroxy-2′-deoxyguanosine; 8-OH-dA, 8-hydroxy-2′-deoxyadenosine; S-cdA, (5′S)-8,5′-cyclo-2′-deoxyadenosine; Fapy-Gua, 2,6-diamino-4-hydroxy-5-formamidopyrimidine; GC–MS, gas chromatography–mass spectrometry; LC–MS, liquid chromatography–mass spectrometry; SIM, selected ion monitoring; •OH, hydroxyl radical.

ionizing radiation and free radical-generating agents by repairing resulting radicals of DNA and/or other cellular components. This occurs via donation of an H atom to radicals, thus converting them back to their original molecule. A well-known example is the chemical repair by GSH of free radical precursors of single- and double-strand breaks in DNA (10, 11). Chemical repair of radicals by GSH competes with oxygen fixation that results in enhancement of radiation-induced damage in living cells (11). GSH can also react with peroxy radicals, preventing them from initiating chain reactions, and with highly reactive hydroxyl radicals ($\cdot\text{OH}$), carbon-centered radicals, alkoxyl radicals, and other reactive species in vivo (4). Furthermore, GSH chelates copper ions and thus weakens their reaction with H_2O_2 to generate $\cdot\text{OH}$ (12).

Although samples from patients with genetic deficiencies of GSH biosynthesis are available and useful for some studies, the nature of these deficiencies has not been well understood. Since GSH metabolism is dynamic, involving many tissues, in vivo studies of the effects of GSH deficiency are worth pursuing further. Treatment with buthionine sulfoximine (BSO), a selective inhibitor of γ -GCS, has been shown to lead to decreased cellular GSH levels, and its application can provide a useful experimental model of GSH deficiency (13, 14). Since GSH is the most frequently found nonprotein intracellular thiol, its depletion by BSO leads to oxidative stress and to an increase in radiation sensitivity (4, 15). Moreover, BSO sensitizes cancer cells to chemotherapy, and the use of BSO as an anticancer agent is currently in clinical trials (16–22).

While damage caused by oxidative stress to any cellular constituent may be detrimental to the cell affected, damage to DNA is of particular concern, since it can lead to mutagenesis, carcinogenesis, and age-related diseases among other biological effects. The mechanisms of formation, repair, and measurement and biological effects of oxidatively induced DNA damage have been reviewed in detail (23). However, the effects of oxidative stress, experimentally induced by GSH deficiency, on cellular DNA are not well understood.

The objective of this study was to investigate oxidatively induced damage to DNA by GSH depletion in different organs of rabbits in vivo. Moreover, we hypothesized that 2-aminoethanesulfonic acid [taurine (Tau)], a semiessential amino acid, may protect the tissues from oxidatively induced DNA damage.

MATERIALS AND METHODS

Materials². Nuclease P1 (from *Penicillium citrinum*) was purchased from United States Biological (Swampscott, MA). Buthionine sulfoximine (BSO), orthophthaldialdehyde, and snake venom phosphodiesterase were obtained from Sigma (St. Louis, MO). Alkaline phosphatase was purchased from Roche Applied Science (Indianapolis, IN). Acetonitrile (HPLC grade) was from Burdick and Jackson (Muskegon, MI). Biomax5 ultrafiltration membranes (5 kDa molecular mass cutoff) from Millipore (Bedford, MA) were used to filter hydrolyzed DNA samples. Water (HPLC grade) for analysis by liquid chromatography–mass spectrometry (LC–MS) was from J. T. Baker (Phillipsburg, NJ). Water purified through a Milli-Q system

(Millipore) was used for all other applications. *N,O*-Bis(trimethylsilyl)trifluoroacetamide containing 1% trimethylchlorosilane was obtained from Pierce Chemicals (Rockford, IL).

Animal Model of GSH Deficiency. The animal experiments were conducted in accordance with guidelines described by the Ethics Committee of the Faculty of Pharmacy of Ege University. A total of 20 rabbits were used in this study. White rabbits of either sex (2.5–3 kg) were divided into four groups. The first group ($n = 5$, BSO group) received a single subcutaneous (sc) injection of BSO (75 mg/kg of body weight/day). To determine the dose of BSO, blood samples were taken from the marginal ear artery on days 0, 8, and 15 from rabbits treated with chronically administered BSO (14 days, 25, 50, and 75 mg/kg of body weight/day, sc). In these blood samples, GSH and GSSG levels and the GSH/GSSG ratio were determined. A dose of 75 mg/kg of body weight/day was selected in these experiments since it resulted in a 50% reduction in the GSH level and GSH/GSSG ratio on the eighth and 15th days. The second group ($n = 5$, control group) received only the vehicle (0.9% NaCl, 0.8 mL/kg of body weight/day). The third group ($n = 5$, Tau group) received Tau in drinking water (1.0%, w/v). The fourth group ($n = 5$, BSO + Tau group) received the same dose of BSO and Tau in drinking water. Throughout the 2 week treatment period, each rabbit was kept in a separate cage and allowed free access to rabbit chow and tap water. At the end of the treatment period, the rabbits ($n = 20$) were sacrificed by means of an overdose of sodium pentobarbital. Heart, brain, liver, and kidney were harvested for the measurement of DNA damage and GSH levels. Tissue samples, after being frozen under liquid nitrogen, were stored at -80°C until the analyses were performed.

Measurement of Tissue GSH Levels. The levels of reduced GSH and total GSH after dithiothreitol reduction in metaphosphoric acid-denatured samples were measured by precolumn derivatization with orthophthaldialdehyde by HPLC with fluorescence detection. Reversed-phase chromatographic conditions included a Macherey/Nagel Nucleosil MN C18 column (250/4.6 mm, 5 μm particle size), an isocratic separation with a sodium acetate (50 mM)/acetonitrile (70:30) mixture at a flow rate of 0.7 mL/min, a column temperature of 30°C , and detector settings for excitation at 340 nm and emission at 420 nm. The level of reduced GSH was directly calculated using the graph of oxidized GSH and that of oxidized GSH from the “total GSH – reduced GSH/2” equation (24). Both levels were expressed as micromoles per gram of wet tissue.

DNA Isolation. Tissues from control and all treatment groups were suspended in 15 mL of polypropylene centrifugation tubes with 3 mL of nuclei lysis buffer [10 mM Tris-HCl, 400 mM NaCl, and 2 mM EDTA (pH 8.2)] and incubated for 60 min at 37°C . The cell lysates were digested overnight at 37°C with 0.2 mL of 10% SDS and 0.5 mL of protease K solution (1 mg of protease K in 1% SDS and 2 mM EDTA). After digestion was complete, 1 mL of saturated NaCl (approximately 6 M) was added to each tube, and then the contents were shaken vigorously for 15 s until foam from the protein appeared. The sample was then incubated for 10 min at 56°C followed by centrifugation at 5000g for 30 min at room temperature. The protein pellet was left at the bottom of the tube, and the supernatant fraction containing the DNA was transferred to another 15 mL polypropylene tube. Two volumes of absolute ethanol kept at room temperature was added, and the tubes were inverted several times until the DNA precipitated. The precipitated DNA strands were removed by spooling. Isolated DNA pellets were washed twice with 70%

²Certain commercial equipment or materials are identified in this paper to specify adequately the experimental procedure. Such identification does not imply recommendation or endorsement by the National Institute of Standards and Technology, nor does it imply that the materials or equipment identified is necessarily the best available for the purpose.

ethanol and centrifuged. After the removal of ethanol, pellets were air-dried for 60 min at room temperature. The DNA was allowed to dissolve in water for 24 h at 4 °C. The UV spectrum of each DNA sample was recorded by absorption spectrophotometry between wavelengths of 200 and 350 nm to ascertain the purity of DNA and an accurate quantification of the DNA concentration. The absorbance at 260 nm was used to measure the DNA concentration of each sample (absorbance of 1 = 50 μ g of DNA/mL). Aliquots (50 μ g) of DNA samples were dried in a SpeedVac under vacuum.

Analysis of DNA Samples. LC–MS with isotope dilution was used to identify and quantify (5'S)-8,5'-cyclo-2'-deoxyadenosine (S-cdA), and 8-hydroxyguanine (8-OH-Gua) and 8-hydroxyadenine (8-OH-Ade), as their nucleoside forms 8-hydroxy-2'-deoxyguanosine (8-OH-dG) and 8-hydroxy-2'-deoxyadenosine (8-OH-dA), respectively (25–27). A stable isotope-labeled analogue of 8-OH-dG, i.e., 8-OH-dG- $^{15}\text{N}_5$, was purchased from Cambridge Isotope Laboratories (Cambridge, MA) and used as an internal standard. Stable isotope-labeled analogues of S-cdA and 8-OH-dA, i.e., S-cdA- $^{15}\text{N}_5$ and 8-OH-dA- $^{15}\text{N}_5$, respectively, were prepared as described previously (28, 29) and used as internal standards. Aliquots (50 μ g) of DNA samples were supplemented with aliquots of internal standards, hydrolyzed with nuclease P1, snake venom phosphodiesterase, and alkaline phosphatase for 24 h, and then analyzed by LC–MS as described previously (29). A Synergi 4 μ Fusion-RP column [25 cm \times 2 mm (inside diameter), 4 μ m particle size] (Phenomenex, Torrance, CA) with a guard column [1 cm \times 2.1 mm (inside diameter)] was used. Solvent A was acetonitrile with water (98:2, v/v), and solvent B was 100% acetonitrile. A gradient of 1% solvent B/min was used. The flow rate was 0.25 mL/min. The column was kept at 40 °C. An aliquot of 25 μ L of filtered samples was injected into the LC column. For identification and quantification, selected ion monitoring (SIM) was used to monitor the characteristic ions of 8-OH-dG (m/z 168 and 306), 8-OH-dG- $^{15}\text{N}_5$ (m/z 173 and 311), 8-OH-dA (m/z 152 and 290), 8-OH-dA- $^{15}\text{N}_5$ (m/z 157 and 295), S-cdA (m/z 164 and 250), and S-cdA- $^{15}\text{N}_5$ (m/z 169 and 255) at the appropriate retention time periods during LC–MS analyses (25–27).

2,6-diamino-4-hydroxy-5-formamidopyrimidine (FapyGua), and 8-OH-Gua were identified and quantified using GC–MS with isotope dilution, following hydrolysis of DNA samples with *Escherichia coli* Fpg to release these lesions (30). Stable isotope-labeled analogue of FapyGua, i.e., FapyGua- ^{13}C , $^{15}\text{N}_2$, was purchased from Cambridge Isotope Laboratories. The stable isotope-labeled analogue of 8-OH-Gua, i.e., 8-OH-Gua- ^{13}C , $^{15}\text{N}_3$, was obtained as described previously (31). Aliquots (50 μ g) of DNA were supplemented with aliquots of FapyGua- ^{13}C , $^{15}\text{N}_2$, and 8-OH-Gua- ^{13}C , $^{15}\text{N}_3$ and hydrolyzed with 2 μ g of *E. coli* Fpg (32). After hydrolysis, precipitation of DNA by ethanol, and subsequent centrifugation, supernatant fractions and DNA pellets were separated. Supernatant fractions were freed from ethanol in a SpeedVac under vacuum, frozen in liquid nitrogen, and lyophilized for 18 h. The dried hydrolysates were trimethylsilylated and then analyzed by GC–MS as described previously (30). For identification and quantification, SIM was used to monitor the characteristic ions of the trimethylsilyl derivatives of FapyGua (m/z 442 and 457), FapyGua- ^{13}C , $^{15}\text{N}_2$ (m/z 445 and 460), 8-OH-Gua (m/z 440 and 455), and 8-OH-Gua- ^{13}C , $^{15}\text{N}_3$ (m/z 444 and 459) (30). The quantification of the monitored compounds was achieved using

integrated areas of the signals of their ions. The levels of 8-OH-Gua measured by GC–MS and LC–MS as its nucleoside 8-OH-dG agreed well with each other.

Statistical Analysis of the Data. Statistical analysis was performed by using GraphPad (San Diego, CA) Prism, version 3.02. The statistical comparisons between the groups were performed by Kruskal–Wallis one-way analysis of variance (ANOVA) followed by a Mann–Whitney test or ANOVA followed by Tukey's multiple comparison test when appropriate. $P < 0.05$ was considered statistically significant.

RESULTS

We hypothesized that the depletion of GSH in vivo causes oxidatively induced DNA damage and leads to its accumulation. To test this hypothesis, we investigated the formation of some typical oxidatively induced DNA lesions and GSH levels in organs of rabbits in vivo treated with the GSH-depleting compound BSO. Furthermore, we hypothesized that the non-essential amino acid Tau, which is abundantly present in most mammalian tissues, including the brain, heart, skeletal muscles, and nervous system (reviewed in refs 33 and 34), may reverse the action of BSO and inhibit DNA damage. We assayed four groups of rabbits, each of which had five animals, namely, the control group and three other groups treated with BSO, BSO and Tau, or Tau. The organs chosen for analysis were liver, kidney, brain, and heart. Rabbits tolerated BSO and Tau treatments well. Tau did not appear to cause any visible side effects. However, corneal opacity was observed in four rabbits from the BSO group. The body weight of the rabbits from each group did not change with the treatment (data not shown). The levels of GSH were measured in liver, kidney, brain, and heart from all groups of rabbits. Treatment with BSO significantly reduced GSH levels in liver (Figure 1A). When animals were fed with Tau at the time of BSO treatment, no significant depletion of GSH was observed when compared to the control group, indicating the protection afforded by Tau against GSH depletion (also compare the BSO group and the BSO + Tau group). Tau alone had no significant effect on GSH level when compared to the control group. In kidney, however, BSO treatment did not significantly affect the GSH level (Figure 1B). As in liver, GSH levels in brain and heart significantly decreased in response to BSO treatment (panels C and D of Figure 1, respectively). Tau significantly prevented GSH depletion by BSO. In heart, however, Tau did not reverse the action of BSO completely and the GSH level was significantly lower than those in the control group and in the Tau group. In both cases, Tau alone had no effect on GSH level when compared to the control group (Figure 1C,D).

We also investigated the formation of some typical oxidatively induced DNA lesions in liver, kidney, brain, and heart of control and treated rabbits. The structure of the lesions identified and quantified are shown in Figure 2. Panels A and B of Figure 3 illustrate the level of 8-OH-Gua in brain and kidney, respectively. No significant differences in the levels of 8-OH-Gua were observed in the DNA of these organs regardless of BSO and BSO/Tau exposure when compared to the control group. 8-OH-Gua could not be measured in the DNA of brain of animals treated with Tau alone (Figure 3A). In liver and heart, however, treatment with BSO caused significant formation of 8-OH-Gua (panels C and D of Figure 3, respectively). In both cases, feeding the animals with Tau at the time of




FIGURE 1: (A) Level of GSH in liver of control animals and animals treated with BSO, BSO and Tau, or Tau. Data are expressed as means of five independent measurements using five animals in each group. Uncertainties are standard deviations. Statistical significance: (a) $p < 0.05$ (compared to control group); (b) $p < 0.05$ (compared to BSO group); and (c) $p < 0.05$ (compared to BSO group). (B) Level of GSH in kidney of control animals and animals treated with BSO, BSO and Tau, or Tau. Data are expressed as means of five independent measurements using five animals in each group. Uncertainties are standard deviations. (C) Level of GSH in brain of control animals and animals treated with BSO, BSO and Tau, or Tau. Data are expressed as means of five independent measurements using five animals in each group. Uncertainties are standard deviations. Statistical significance: (a) $p < 0.05$ (compared to control group); (b) $p < 0.05$ (compared to BSO group); and (c) $p < 0.05$ (compared to BSO group). (D) Level of GSH in heart of control animals and animals treated with BSO, BSO and Tau, or Tau. Data are expressed as means of five independent measurements using five animals in each group. Uncertainties are standard deviations. Statistical significance: (a) $p < 0.05$ (compared to control group); (b) $p < 0.05$ (compared to BSO group); (c) $p < 0.05$ (compared to BSO + Tau group); (d) $p < 0.05$ (compared to BSO + Tau group); and (e) $p < 0.05$ (compared to control group).




FIGURE 2: Structures of the DNA lesions examined in this work.

BSO treatment significantly inhibited the formation of 8-OH-Gua (Figure 3C,D). Tau alone had no effect on the level of 8-OH-Gua observed in liver and heart of control animals.

In contrast to 8-OH-Gua, BSO treatment caused significant formation of FapyGua in brain when compared to the control group, and Tau inhibited it (Figure 4A). In this case, FapyGua could not be detected in brain of animals fed with Tau alone. Similar results were observed in liver and heart. BSO treatment significantly increased the level of FapyGua. Tau inhibited the formation of this modified DNA base in these tissues (Figure

4B,C). As in the case of 8-OH-Gua, treatment with BSO, BSO and Tau, or Tau had no significant effect on the level of FapyGua in kidney (Figure 4D). S-cdA and 8-OH-Ade were detected and quantified in liver only. Statistically significant formation of both S-cdA and 8-OH-dA was observed in response to BSO treatment (panels A and B of Figure 5, respectively). Tau inhibited the formation of these lesions. 8-OH-Ade could not be detected in liver of Tau-treated animals (Figure 5B).

DISCUSSION

The model of continuous depletion of GSH used in this study depends on the inhibition of the enzyme γ -GCS by BSO in mice (5, 35, 36), rats (37–40), and rabbits (41). This experimental model of GSH deficiency has also been used as a model of oxidative stress (15) and as an experimental model of hypertension (37, 42). In this study, we show for the first time that GSH depletion induced by BSO treatment results in formation of oxidatively induced DNA lesions in several organs of rabbits in vivo. Thus, our results clearly demonstrate the protection afforded by GSH in vivo against oxidatively induced DNA damage. Moreover, we show the protective effect of Tau against DNA damage induced by GSH depletion.

Consistent with the results of previous studies (36, 38), subcutaneously administered BSO significantly decreased GSH levels in liver, heart, and brain of animals. However, it exhibited no significant effect on GSH level in kidney, suggesting an organ-specific response in vivo to a GSH-depleting agent. Tau in drinking water of animals inhibited a decrease in GSH levels in liver, heart, and brain. Tau is found at high concentrations in mammalian tissues (43, 44). An important role in many




FIGURE 3: (A) Level of 8-OH-Gua in brain of control animals and animals treated with BSO or BSO and Tau. Data are expressed as means of five independent measurements using five animals in each group. Uncertainties are standard deviations. (B) Level of 8-OH-Gua in kidney of control animals and animals treated with BSO, BSO and Tau, or Tau. Data are expressed as means of five independent measurements using five animals in each group. Uncertainties are standard deviations. (C) Level of 8-OH-Gua in liver of control animals and animals treated with BSO, BSO and Tau, or Tau. Data are expressed as means of five independent measurements using five animals in each group. Uncertainties are standard deviations. Statistical significance: (a) $p < 0.05$ (compared to control group). (D) Level of 8-OH-Gua in heart of control animals and animals treated with BSO, BSO and Tau, or Tau. Data are expressed as means of five independent measurements using five animals in each group. Uncertainties are standard deviations. Statistical significance: (a) $p < 0.001$ (compared to control group); and (b and c) $p < 0.001$ (compared to BSO group).




FIGURE 4: (A) Level of FapyGua in brain of control animals and animals treated with BSO or BSO and Tau. Data are expressed as means of five independent measurements using five animals in each group. Uncertainties are standard deviations. Statistical significance: (a) $p < 0.001$ (compared to control group); and (b) $p < 0.001$ (compared to BSO group). (B) Level of FapyGua in liver of control animals and animals treated with BSO, BSO and Tau, or Tau. Data are expressed as means of five independent measurements using five animals in each group. Uncertainties are standard deviations. Statistical significance: (a) $p < 0.001$ (compared to control group); and (b and c) $p < 0.001$ (compared to BSO group). (C) Level of FapyGua in heart of control animals and animals treated with BSO, BSO and Tau, or Tau. Data are expressed as means of five independent measurements using five animals in each group. Uncertainties are standard deviations. Statistical significance: (a) $p < 0.001$ (compared to control group); and (b and c) $p < 0.001$ (compared to BSO group). (D) Level of FapyGua in kidney of control animals and animals treated with BSO, BSO and Tau, or Tau. Data are expressed as means of five independent measurements using five animals in each group. Uncertainties are standard deviations.

physiological processes has been attributed to this nonessential amino acid, such as regulation of the cardiovascular system and blood pressure, cell proliferation, and protection against oxidative

stress, neurodegenerative diseases, and atherosclerosis among other marked activities on various disorders (reviewed in refs 33, 34, and 45). The exact mechanism for the Tau-induced protective




FIGURE 5: (A) Level of S-cdA in liver of control animals and animals treated with BSO, BSO and Tau, or Tau. Data are expressed as means of five independent measurements using five animals in each group. Uncertainties are standard deviations. Statistical significance: (a) $p < 0.05$ (compared to control group); and (b) $p < 0.01$ (compared to BSO group). (B) Level of 8-OH-Ade in liver of control animals and animals treated with BSO or BSO and Tau. Data are expressed as means of five independent measurements using five animals in each group. Uncertainties are standard deviations. Statistical significance: (a) $p < 0.001$ (compared to control group); and (b) $p < 0.01$ (compared to BSO group).

effect against GSH depletion is not well-known. Feeding animals with Tau during BSO treatment inhibited the formation of DNA lesions detected in this study. This effect is likely to result from the inhibition of GSH depletion by Tau rather than from its antioxidant action. Tau is unlikely to have a biological role as an antioxidant, because it is a poor antioxidant *in vitro* and because Tau chloramines resulting from its reaction with hypochlorous acid can possibly oxidize biomolecules (4, 46). In contrast, an effective antioxidant role has been attributed to hypotaurine *in vivo*, which is the precursor of Tau, as a scavenger of $\cdot\text{OH}$ (4, 44). Hypotaurine is converted into Tau by certain reactive species, including $\cdot\text{OH}$ and hypochlorous acid (4).

It is important to emphasize that, in this work, depletion of GSH correlated well with formation of DNA lesions, indicating the role of GSH in preventing oxidatively induced DNA damage. Simultaneous inhibition of GSH depletion and DNA damage by Tau strongly supports this conclusion. Kidney was the only organ that did not exhibit GSH depletion by BSO and DNA damage observed in the other organs. This result also supports the correlation of GSH depletion with DNA damage. With respect to oxidatively induced DNA damage in this model of GSH deficiency, liver was found to be the most affected organ with more DNA lesions detected than in other organs, indicating the importance of GSH for protection against oxidatively induced DNA damage in this organ. Thus, the formation of S-cdA and 8-OH-Ade was observed in liver only. The greater DNA damage in GSH-depleted liver may well be a consequence of the role that this organ plays in synthesis and secretion of GSH. As the main source of plasma GSH, secretion of GSH from the liver into plasma provides substrates for GSH synthesis in other organs, and different transporters are involved in this process (4, 47). Overall, our results strongly suggest organ-specific DNA damage oxidatively induced by GSH depletion *in vivo*.

The role of GSH in preventing DNA damage by oxidative stress is of great interest (48–51). In our study, we demonstrated the formation of FapyGua, 8-OH-Gua, 8-OH-Ade, and S-cdA in DNA of several organs of rabbits by GSH depletion. These compounds are typical products of reactions of $\cdot\text{OH}$ with purine bases in DNA. Their mechanisms of formation have previously been discussed in detail (for reviews, see refs 23, 52, and 53). In spite of the blood–brain barrier, we observed a significant decrease in the GSH level in the brain of BSO-treated animals. With regard to DNA damage in this organ, the background level of 8-OH-Gua was not significantly affected by BSO treatment. In contrast, FapyGua was significantly formed in conjunction with the decreased GSH level in brain. In heart and liver, however, the

formation of both 8-OH-Gua and FapyGua was observed, and this correlated with decreased levels of GSH. Tau treatment prevented the formation of these two lesions. Tau crosses the blood–brain barrier (54, 55) and thus may play an important role in preventing DNA damage in brain as our results suggest. The difference in the formation of DNA lesions between different tissues is noteworthy. 8-OH-Gua and FapyGua result from the same parent OH adduct radical of guanine by one-electron oxidation and by one-electron reduction, respectively (reviewed in refs 23 and 53). Thus, the ratio of the yields of 8-OH-Gua and FapyGua may be affected by the redox status of cells and by the availability of transition metal ions (4). These factors may vary among different tissues, affecting the background levels and formation of these lesions. The redox status in brain may be different from that in other organs, favoring the formation of FapyGua over that of 8-OH-Gua. In terms of cellular repair, there are also some differences between these two lesions. OGG1 is the only DNA repair enzyme that removes 8-OH-Gua from DNA in mammalian cells (reviewed in ref 56). FapyGua is also removed from DNA by OGG1 with similar excision kinetics. In addition, FapyGua is the substrate of NEIL1, which is not specific for 8-OH-Gua. These differences may play a role in the different levels of these two lesions observed *in vivo*.

In conclusion, we demonstrated, for the first time, accumulation of some major products of oxidatively induced damage to DNA in several organs of rabbits due to GSH depletion *in vivo*, indicating the role of GSH in overall protection of cells against this type of DNA damage. Moreover, we showed the protective effect of Tau against oxidatively induced DNA damage resulting from GSH depletion. These findings may have implications in pathologies associated with oxidative stress and/or defective antioxidant responses and improve our understanding of the effect of BSO in increasing the efficacy of therapeutic agents in cancer therapy.

ACKNOWLEDGMENT

We are grateful to Dokuz Eylul University Medical School Learning Resources Center Research Laboratory, especially to Dr. Memduh Bulbul for helpful technical support with HPLC measurements.

REFERENCES

1. Anderson, M. E. (1998) Glutathione: An overview of biosynthesis and modulation. *Chem.-Biol. Interact.* 111–112, 1–14.
2. Lu, S. C. (2000) Regulation of glutathione synthesis. *Curr. Top. Cell. Regul.* 36, 95–116.

3. Jones, D. P. (2002) Redox potential of GSH/GSSG couple: Assay and biological significance. *Methods Enzymol.* 348, 93–112.
4. Halliwell, B., and Gutteridge, J. M. C. (2007) *Free Radicals in Biology and Medicine*, 4th ed., Oxford University Press, Oxford, U.K.
5. Martensson, J., Jain, A., Stole, E., Frayer, W., Auld, P. A., and Meister, A. (1991) Inhibition of glutathione synthesis in the newborn rat: A model for endogenously produced oxidative stress. *Proc. Natl. Acad. Sci. U.S.A.* 88, 9360–9364.
6. Meister, A. (1991) Glutathione deficiency produced by inhibition of its synthesis, and its reversal: Applications in research and therapy. *Pharmacol. Ther.* 51, 155–194.
7. Uhlig, S., and Wendel, A. (1992) The physiological consequences of glutathione variations. *Life Sci.* 51, 1083–1094.
8. Wu, G., Fang, Y. Z., Yang, S., Lupton, J. R., and Turner, N. D. (2004) Glutathione metabolism and its implications for health. *J. Nutr.* 134, 489–492.
9. Dalton, T. P., Chen, Y., Schneider, S. N., Nebert, D. W., and Shertzer, H. G. (2004) Genetically altered mice to evaluate glutathione homeostasis in health and disease. *Free Radical Biol. Med.* 37, 1511–1526.
10. Prise, K. M., Gillies, N. E., and Michael, B. D. (1999) Further evidence for double-strand breaks originating from a paired radical precursor from studies of oxygen fixation processes. *Radiat. Res.* 151, 635–641.
11. von Sonntag, C. (2006) *Free-Radical-Induced DNA Damage and Its Repair*, Springer, Heidelberg, Germany.
12. Hanna, P. M., and Mason, R. P. (1992) Direct evidence for inhibition of free radical formation from Cu(I) and hydrogen peroxide by glutathione and other potential ligands using the EPR spin-trapping technique. *Arch. Biochem. Biophys.* 295, 205–213.
13. Meister, A., and Anderson, M. E. (1983) Glutathione. *Annu. Rev. Biochem.* 52, 711–760.
14. Jain, A., Martensson, J., Stole, E., Auld, P. A., and Meister, A. (1991) Glutathione deficiency leads to mitochondrial damage in brain. *Proc. Natl. Acad. Sci. U.S.A.* 88, 1913–1917.
15. Cattani, V., Mercier, N., Gardner, J. P., Regnault, V., Labat, C., Maki-Jouppila, J., Nzietchueng, R., Benetos, A., Kimura, M., Aviv, A., and Lacolley, P. (2008) Chronic oxidative stress induces a tissue-specific reduction in telomere length in CAST/Ei mice. *Free Radical Biol. Med.* 44, 1592–1598.
16. Bailey, H. H., Mulcahy, R. T., Tutsch, K. D., Arzooonian, R. Z., Alberti, D., Tombes, M. B., Wilding, G., Pomplun, M., and Spriggs, D. R. (1994) Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: An attempt at modulation of glutathione. *J. Clin. Oncol.* 12, 194–205.
17. O'Dwyer, P. J., Hamilton, T. C., LaCreta, F. P., Gallo, J. M., Kilpatrick, D., Halbherr, T., Brennan, J., Bookman, M. A., Hoffman, J., Young, R. C., Comis, R. L., and Ozols, R. F. (1996) Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. *J. Clin. Oncol.* 14, 249–256.
18. Bailey, H. H., Ripple, G., Tutsch, K. D., Arzooonian, R. Z., Alberti, D., Feierabend, C., Mahvi, D., Schink, J., Pomplun, M., Mulcahy, R. T., and Wilding, G. (1997) Phase I study of continuous-infusion L-S, R-buthionine sulfoximine with intravenous melphalan. *J. Natl. Cancer Inst.* 89, 1789–1796.
19. Schnelldorfer, T., Gansauge, S., Gansauge, F., Schlosser, S., Beger, H. G., and Nussler, A. K. (2000) Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells. *Cancer* 89, 1440–1447.
20. Hamilton, D., Fotouhi-Ardakani, N., and Batist, G. (2002) *Clinically Relevant Resistance in Cancer Chemotherapy*, Springer, New York.
21. Rudin, C. M., Yang, Z., Schumaker, L. M., VanderWee, D. J., Newkirk, K., Egorin, M. J., Zuhowski, E. G., and Cullen, K. J. (2003) Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. *Cancer Res.* 63, 312–318.
22. Lewis-Wambi, J. S., Kim, H. R., Wambi, C., Patel, R., Pyle, J. R., Klein-Szanto, A. J., and Jordan, V. C. (2008) Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis. *Breast Cancer Res.* 10, R104.
23. Evans, M. D., Dizdaroglu, M., and Cooke, M. S. (2004) Oxidative DNA damage and disease: Induction, repair and significance. *Mutat. Res.* 567, 1–61.
24. Cereser, C., Guichard, J., Drai, J., Bannier, E., Garcia, I., Boget, S., Parvaz, P., and Revol, A. (2001) Quantitation of reduced and total glutathione at the femtomole level by high-performance liquid chromatography with fluorescence detection: Application to red blood cells and cultured fibroblasts. *J. Chromatogr., B: Biomed. Sci. Appl.* 752, 123–132.
25. Dizdaroglu, M., Jaruga, P., and Rodriguez, H. (2001) Identification and quantification of 8,5'-cyclo-2'-deoxyadenosine in DNA by liquid chromatography/mass spectrometry. *Free Radical Biol. Med.* 30, 774–784.
26. Dizdaroglu, M., Jaruga, P., and Rodriguez, H. (2001) Measurement of 8-hydroxy-2'-deoxyguanosine in DNA by high-performance liquid chromatography-mass spectrometry: Comparison with measurement by gas chromatography-mass spectrometry. *Nucleic Acids Res.* 29, E12.
27. Jaruga, P., Rodriguez, H., and Dizdaroglu, M. (2001) Measurement of 8-hydroxy-2'-deoxyadenosine in DNA by liquid chromatography/mass spectrometry. *Free Radical Biol. Med.* 31, 336–344.
28. Birincioglu, M., Jaruga, P., Chowdhury, G., Rodriguez, H., Dizdaroglu, M., and Gates, K. S. (2003) DNA base damage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine). *J. Am. Chem. Soc.* 125, 11607–11615.
29. Jaruga, P., Theruvathu, J., Dizdaroglu, M., and Brooks, P. J. (2004) Complete release of (5'S)-8,5'-cyclo-2'-deoxyadenosine from dinucleotides, oligodeoxynucleotides and DNA, and direct comparison of its levels in cellular DNA with other oxidatively induced DNA lesions. *Nucleic Acids Res.* 32, e87.
30. Jaruga, P., Kirkali, G., and Dizdaroglu, M. (2008) Measurement of formamidopyrimidines in DNA. *Free Radical Biol. Med.* 45, 1601–1609.
31. Nelson, V. C. (1996) Synthesis of isotopically labelled DNA degradation products for use in mass spectrometric studies of cellular DNA damage. *J. Labelled Compd. Radiopharm.* 38, 713–723.
32. Reddy, P., Jaruga, P., O'Connor, T., Rodriguez, H., and Dizdaroglu, M. (2004) Overexpression and rapid purification of *Escherichia coli* formamidopyrimidine-DNA glycosylase. *Protein Expression Purif.* 34, 126–133.
33. Bouckenoghe, T., Remacle, C., and Reusens, B. (2006) Is taurine a functional nutrient? *Curr. Opin. Clin. Nutr. Metab. Care* 9, 728–733.
34. Brosnan, J. T., and Brosnan, M. E. (2006) The sulfur-containing amino acids: An overview. *J. Nutr.* 136, 1636S–1640S.
35. Watanabe, T., Sagisaka, H., Arakawa, S., Shibaya, Y., Watanabe, M., Igarashi, I., Tanaka, K., Totsuka, S., Takasaki, W., and Manabe, S. (2003) A novel model of continuous depletion of glutathione in mice treated with L-buthionine (S,R)-sulfoximine. *J. Toxicol. Sci.* 28, 455–469.
36. Limon-Pacheco, J. H., Hernandez, N. A., Fanjul-Moles, M. L., and Gonshebb, M. E. (2007) Glutathione depletion activates mitogen-activated protein kinase (MAPK) pathways that display organ-specific responses and brain protection in mice. *Free Radical Biol. Med.* 43, 1335–1347.
37. Vaziri, N. D., Wang, X. Q., Oveisi, F., and Rad, B. (2000) Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. *Hypertension* 36, 142–146.
38. Ganafa, A. A., Socci, R. R., Eatman, D., Silvestrova, N., Abukhalaf, I. K., and Bayorh, M. A. (2002) Acute inhibition of glutathione biosynthesis alters endothelial function and blood pressure in rats. *Eur. J. Pharmacol.* 454, 217–223.
39. Iwata, C., Wang, X., Uchida, K., Nakanishi, N., and Hattori, Y. (2007) Buthionine sulfoximine causes endothelium dependent hyper-relaxation and hypoadiponectinemia. *Life Sci.* 80, 873–878.
40. Hashimoto, K., Takasaki, W., Yamoto, T., Manabe, S., Sato, I., and Tsuda, S. (2008) Effect of glutathione (GSH) depletion on DNA damage and blood chemistry in aged and young rats. *J. Toxicol. Sci.* 33, 421–429.
41. Haramaki, N., Ikeda, H., Takajo, Y., Katoh, A., Kanaya, S., Shintani, S., Haramaki, R., Murohara, T., and Imaizumi, T. (2001) Long-term smoking causes nitroglycerin resistance in platelets by depletion of intraplatelet glutathione. *Arterioscler., Thromb., Vasc. Biol.* 21, 1852–1856.
42. Bandy, A. A., Muhammad, A. B., Fazili, F. R., and Lokhandwala, M. (2007) Mechanisms of oxidative stress-induced increase in salt sensitivity and development of hypertension in Sprague-Dawley rats. *Hypertension* 49, 664–671.
43. Learn, D. B., Fried, V. A., and Thomas, E. L. (1990) Taurine and hypotaurine content of human leukocytes. *J. Leukocyte Biol.* 48, 174–182.
44. Green, T. R., Fellman, J. H., Eicher, A. L., and Pratt, K. L. (1991) Antioxidant role and subcellular location of hypotaurine and taurine in human neutrophils. *Biochim. Biophys. Acta* 1073, 91–97.
45. Huxtable, R. J. (1992) Physiological actions of taurine. *Physiol. Rev.* 72, 101–163.
46. Aruoma, O. I., Halliwell, B., Hoey, B. M., and Butler, J. (1988) The antioxidant action of taurine, hypotaurine and their metabolic precursors. *Biochem. J.* 256, 251–255.

47. Ballatori, N., Hammond, C. L., Cunningham, J. B., Krance, S. M., and Marchan, R. (2005) Molecular mechanisms of reduced glutathione transport: Role of the MRP/CFTR/ABCC and OATP/SLC21A families of membrane proteins. *Toxicol. Appl. Pharmacol.* 204, 238–255.
48. Rojas, E., Valverde, M., Kala, S. V., Kala, G., and Lieberman, M. W. (2000) Accumulation of DNA damage in the organs of mice deficient in γ -glutamyltranspeptidase. *Mutat. Res.* 447, 305–316.
49. Reliene, R., and Schiestl, R. H. (2006) Glutathione depletion by buthionine sulfoximine induces DNA deletions in mice. *Carcinogenesis* 27, 240–244.
50. Langie, S. A., Knaapen, A. M., Houben, J. M., van Kempen, F. C., de Hoon, J. P., Gottschalk, R. W., Godschalk, R. W., and van Schooten, F. J. (2007) The role of glutathione in the regulation of nucleotide excision repair during oxidative stress. *Toxicol. Lett.* 168, 302–309.
51. Yadav, U. C., Ramana, K. V., Awasthi, Y. C., and Srivastava, S. K. (2008) Glutathione level regulates HNE-induced genotoxicity in human erythroleukemia cells. *Toxicol. Appl. Pharmacol.* 227, 257–264.
52. Jaruga, P., and Dizdaroglu, M. (2008) 8,5'-Cyclopurine-2'-deoxynucleosides in DNA: Mechanisms of formation, measurement, repair and biological effects. *DNA Repair* 7, 1413–1425.
53. Dizdaroglu, M., Kirkali, G., and Jaruga, P. (2008) Formamidopyrimidines in DNA: Mechanisms of formation, repair, and biological effects. *Free Radical Biol. Med.* 45, 1610–1621.
54. Urquhart, N., Perry, T. L., Hansen, S., and Kennedy, J. (1974) Passage of taurine into adult mammalian brain. *J. Neurochem.* 22, 871–872.
55. Tsuji, A., and Tamai, I. (1996) Sodium- and chloride-dependent transport of taurine at the blood-brain barrier. *Adv. Exp. Med. Biol.* 403, 385–391.
56. Dizdaroglu, M. (2005) Base-excision repair of oxidative DNA damage by DNA glycosylases. *Mutat. Res.* 591, 45–59.